Fluorescent protein biosensor for rapid acrylamide detection at ppb levels

Overview

This solution offers a fluorescent protein (FP) biosensor platform designed for the rapid, sensitive, and cost-effective detection of acrylamide, a known carcinogen and neurotoxin commonly found in drinking water and certain cooked foods. The technology addresses the need for simple field-deployable or laboratory screening tools capable of detecting acrylamide at the low single-digit parts-per-billion (ppb) level in approximately 10 minutes, without the use of harmful chemicals or complex instrumentation.

The core innovation lies in engineering redox-sensitive green fluorescent proteins (roGFPs) whose fluorescent intensity changes predictably upon covalent reaction between acrylamide and strategically positioned cysteine residues on the protein. By measuring this intensity change with a standard fluorescent spectrometer, acrylamide concentration in a sample can be quantified. The platform is envisioned as an inexpensive alternative to traditional analytical methods such as mass spectrometry.

Technical specifications

Key features:

• Biosensing mechanism: Acrylamide covalently conjugates to cysteine residues on engineered roGFPs, causing a measurable reduction in fluorescent intensity proportional to acrylamide concentration
• Detection target: Acrylamide at low single-digit ppb levels in aqueous samples such as drinking water
• Assay time: Approximately 10 minutes per measurement, including simple mixing and short heating steps
• Instrumentation: Compatible with standard fluorescent spectrometers; no specialized or hazardous reagents required
• Manufacturing: Recombinant proteins expressed and purified in bacterial host systems, enabling low-cost production
• Protein engineering pipeline: Integrates computational screening of roGFP variant libraries (with diverse cysteine mutations) with experimental validation to identify optimal biosensor candidates
• Format flexibility: Proprietary protein assembly systems enable processing of FP biosensors into particles or films to enhance sensing performance and broaden deployment options

Proven platform expertise: The research team has previously developed FP-based biosensors for other targets, including calcium ion detection at nanomolar concentrations, with demonstrated applications in imaging neural activity in neurons and brain tissue.

Technology readiness level

The technology is currently at an early-to-mid stage of development (TRL 3–4). The underlying biosensing principle—acrylamide conjugation to cysteine residues on roGFPs causing fluorescence changes—has been established and supported by prior expertise in engineering FP biosensors for ions and small molecules. Future validation efforts will focus on engineering robust recombinant roGFP variants sensitive at the ppb level, optimizing reaction conditions for improved sensitivity, and validating quantification performance across a range of acrylamide concentrations. This validation phase is estimated at approximately six months and includes a partnership opportunity for sample analysis. Commercial deployment would require further refinement of assay protocols, scalability testing, and field validation studies.